▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3231 by analyst upside · 2026-11-13
AMRX
Amneal Pharmaceuticals, Inc.
Healthcare · Market Cap $8B · P/E 54.2x
ANALYST PRICE TARGET
+11.9%
implied upside to consensus target
Current Price $21.7
Consensus Target $24.29
Bull Target $28.0
Bear Target $20.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
4
Hold
0
Sell
0
52-Week Low $11.39
52-Week High $22.07
YTD Return +71.4%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) 54.2x
Forward P/E 17.6x
EPS (TTM) $0.40
PEG Ratio 2.06
Dividend Yield N/A
Revenue (TTM) $3.2B
Profit Margin 4.2%
52-WEEK RANGE
52-Week Low $11.39
52-Week High $22.07
Current Price $21.7
Bear Target $20.0
Bull Target $28.0
● Now $21.7 ● Target $24.29
TRADING DATA
Avg Volume 3.2M
YTD Return +71.4%
Analyst Count 7
Consensus Buy
Upside to Target +11.9%
Last Updated 2026-11-13

ANALYST SUMMARY

Amneal Pharmaceuticals, Inc. (AMRX) is currently trading at $21.7 with a Wall Street consensus price target of $24.29, implying potential upside of 11.9% over the next 12 months. 7 analysts currently cover AMRX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $28.0, while the most cautious has a target of $20.0.

AMRX operates in the Healthcare sector with a market capitalisation of $8B. The stock is up 71.4% year-to-date and is currently trading near the upper end of its 52-week range of $11.39 – $22.07.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AMRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners - Reiterated
Outperform → Outperform 2026-11-05 29% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-11-04 43% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-10-22 43% win rate (7 calls)
Oppenheimer ● Initiated
Outperform 2026-09-23 14% win rate (7 calls)
Barclays - Reiterated
Overweight → Overweight 2026-09-17 Building track record
Leerink Partners ● Initiated
Outperform 2026-09-09 29% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2026-08-03 33% win rate (6 calls)
UBS - Reiterated
Buy → Buy 2026-07-15 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
16/30
Consensus clarity
23/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →